Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Hussain

Showing results (11-20 of 213) with videos related to

Pageof 22
Sort By:
Expert Opinion on Investigational Drugs|August 13, 2024
Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?Sarah E Fenton, Maha Hussain
NEJM Evidence|February 6, 2024
Should We "PROpel" Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?David J VanderWeele, Maha Hussain
Current Treatment Options in Oncology|January 30, 2024
Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet TherapyAnthony V Serritella, Maha Hussain
Critical Reviews in Oncology/Hematology|August 6, 2003
Molecular biology of transitional cell carcinomaSana Al-Sukhun, Maha Hussain
Urologic Oncology|July 3, 2008
Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patientKathleen W Beekman, Maha Hussain
Cancer Journal (Sudbury, Mass.)|October 18, 2016
Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate CancerZachery R Reichert, Maha Hussain
Cancer Journal (Sudbury, Mass.)|February 28, 2008
Promising novel cytotoxic agents and combinations in metastatic prostate cancerDeborah A Bradley, Maha Hussain
Cancer|April 4, 2003
Current understanding of the biology of advanced bladder cancerSana Al-Sukhun, Maha Hussain
Current Oncology Reports|April 19, 2006
Targeted approaches for the management of metastatic prostate cancerKathleen W Beekman, Maha Hussain
Clinical Advances in Hematology & Oncology : H&O|January 6, 2021
PARP inhibitors in prostate cancer: practical guidance for busy cliniciansDavid J VanderWeele, Maha Hussain
Pageof 22

Showing results (11-20 of 213) with videos related to

Sort By:
Pageof 22
Expert Opinion on Investigational Drugs|August 13, 2024
Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?Sarah E Fenton, Maha Hussain
NEJM Evidence|February 6, 2024
Should We "PROpel" Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?David J VanderWeele, Maha Hussain
Current Treatment Options in Oncology|January 30, 2024
Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet TherapyAnthony V Serritella, Maha Hussain
Critical Reviews in Oncology/Hematology|August 6, 2003
Molecular biology of transitional cell carcinomaSana Al-Sukhun, Maha Hussain
Urologic Oncology|July 3, 2008
Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patientKathleen W Beekman, Maha Hussain
Cancer Journal (Sudbury, Mass.)|October 18, 2016
Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate CancerZachery R Reichert, Maha Hussain
Cancer Journal (Sudbury, Mass.)|February 28, 2008
Promising novel cytotoxic agents and combinations in metastatic prostate cancerDeborah A Bradley, Maha Hussain
Cancer|April 4, 2003
Current understanding of the biology of advanced bladder cancerSana Al-Sukhun, Maha Hussain
Current Oncology Reports|April 19, 2006
Targeted approaches for the management of metastatic prostate cancerKathleen W Beekman, Maha Hussain
Clinical Advances in Hematology & Oncology : H&O|January 6, 2021
PARP inhibitors in prostate cancer: practical guidance for busy cliniciansDavid J VanderWeele, Maha Hussain
Pageof 22